Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products From Schering-Plough
Posted on: Wednesday, 23 April 2008, 18:00 CDT
Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal.
Specifically, Pfizer Animal Health will acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering the following categories:
Swine E. coli Vaccines
Equine Influenza and Tetanus Vaccines
Ruminant Neonatal and Clostridia Vaccines
Rabies Vaccines
Companion Animal Veterinary Specialty Products
Parasiticides & Anti-inflammatories
The acquisition is subject to certain closing conditions, including antitrust approval. Terms of the agreement were not disclosed.
Pfizer Animal Health's Europe President, Albert Bourla, said that the acquisition will enable Pfizer Animal Health Europe to build upon its comprehensive animal health solutions for veterinarians and their clients - farmers and pet owners - in Europe. Bourla added, "We look forward to offering veterinarians additional preventative therapies and treatments along with our technical expertise and services to ensure that animals receive the best care possible."
About Pfizer Animal Health
Pfizer Inc (NYSE: PFE), the world's largest research-based pharmaceutical company, is a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Animal Health is dedicated to improving the safety, quality and productivity of the world's food supply by enhancing the health of livestock and poultry; and in helping companion animals live longer and healthier lives. For additional information on Pfizer's portfolio of animal products, visit www.PfizerAH.com.
DISCLOSURE NOTICE: The information contained in this release is as of April 23, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the agreement by Pfizer to acquire certain animal health products from Schering-Plough that involve substantial risks and uncertainties. Such risks and uncertainties include, among others, the satisfaction of the conditions to closing the agreement. A further list and description of risks and uncertainties can be found in Pfizer's Annual Report of Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Source: Business Wire
Related Articles
- avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaa's Product
- Quick-Med Technologies, Inc. Signs Joint Development Agreement With a Leading Provider of Health Care Products
- Crucell Announces Vaccine Development Agreement With Wyeth Pharmaceuticals
- Health Enhancement Products Announces the Signing of a Broker Agreement With Natural Brokers, Inc.
- Health Enhancement Products Announces Dr. Robert Cohen to Join Scientific Advisory Board
- Pfizer Health Solutions Selects D2Hawkeye to Provide Risk Stratification to Florida State Medicaid Project
- Health Enhancement Products to Create Pharmaceutical Division to Pursue Potential Pharmaceutical Applications for ProAlgaZyme
- avVaa World Health Care Products Announces New Spokesperson Agreement With Lynn Palm/Palm Partnership Training
- avVaa World Health Care Products Board Member and Former Pharmaceutical VP Darrell Stevens Named Interim CEO
- avVaa World Health Care Products Signs New Spokesman
User Comments (0)

RSS Feeds